Xeris Pharmaceuticals | XERS - Ebitda


Xeris Pharmaceuticals reported $17.42M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Celltrion KRW 374.56B 352.67B Sep/2025
Cspc Pharmaceutical CNY 2.19B 21.88M Dec/2024
Deva Holding AS TRY 882.9M 201.7M Sep/2023
Dianthus Therapeutics USD -40.19M 5.36M Sep/2025
Divis Laboratories Ltd INR 8.9B 20M Dec/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Kangmei Pharma CNY 17.3M 20.56M Jun/2025
Knight Therapeutics CAD 20.99M 5.48M Sep/2025
Laboratorios Farma EUR 34.94M 102.95M Jun/2025
Malin Corporation EUR -1.1M 200K Dec/2024
Medical Developments International AUD 1.78M 3.78M Dec/2024
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neuren Pharmaceuticals AUD 11.14M 165.56M Dec/2025
Organigram Holdings CAD 6.15M 455K Sep/2025
Pacira USD 38.71M 10.65M Dec/2025
Perrigo USD 258.8M 37.3M Sep/2025
Pharma Mar EUR 44.96M 46.94M Dec/2025
Qiagen NV USD 249.69M 56.53M Dec/2025
Sartorius EUR 277.4M 30.5M Dec/2025
Sino Biopharmaceutical CNY 2.59B 1.57B Dec/2024
Supernus Pharmaceuticals USD 48.5M 6.6M Dec/2025
Tilray USD 8.36M 1.82M Sep/2025
Zhangzhou Pientzehuang Pharmaceutical CNY 531.61M 658.23M Jun/2025